SCHEMBL15568723

SCHEMBL15568723

O=S(=O)(CCO)Cc1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.43
MMP1 P03956 2/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP13 P45452 2/20 0.41
MMP3 P08254 1/20 0.41
MMP7 P09237 1/20 0.41
EGFR P00533 3/20 0.39
ERBB2 P04626 3/20 0.39
PLCG1 P19174 1/20 0.38
POLB P06746 1/20 0.36
NPC1 O15118 1/20 0.36
CA2 P00918 4/20 0.35
CA1 P00915 3/20 0.35
CA9 Q16790 2/20 0.35
MMP8 P22894 1/20 0.35
MEN1 O00255 1/20 0.35
HTR2A P28223 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
CA12 O43570 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9574362 0.89 KMT2A (0.50) KMT2AMMP1MMP2MMP9MMP13
SCHEMBL1138688 0.83 PLCG1 (0.46) KMT2AMMP1MMP2MMP9MMP13
SCHEMBL14426941 0.80 KMT2A (0.43) KMT2AMMP1MMP2MMP9MMP13
SCHEMBL1202589 0.80 RECQL (0.46) KMT2AMMP1MMP2MMP9MMP13
SCHEMBL15568656 0.80 KMT2A (0.66) KMT2APOLBCA2CA1CA9
SCHEMBL15568647 0.80 USP2 (0.44) KMT2AEGFRERBB2POLBMEN1
SCHEMBL10482000 0.79 CA1 (0.50) KMT2AMMP1MMP2MMP9MMP13
SCHEMBL21928927 0.78 CA12 (0.43) MMP2EGFRERBB2CA2CA1
SCHEMBL8997396 0.77 TSHR (0.50) KMT2APOLBCA2CA1CA9
SCHEMBL20155480 0.77 PLCG1 (0.41) KMT2AEGFRERBB2PLCG1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2882727-B1 IMMUNOMODULATORY COMPOUNDS UNIV STRATHCLYDE (GB) 2021-01-20 EP disclosed
EP-2882727-B1 IMMUNOMODULATORY COMPOUNDS UNIV STRATHCLYDE (GB) 2021-01-20 EP disclosed
US-9598386-B2 Immunomodulatory compounds UNIVERSITY OF STRATHCLYDE (GB) 2017-03-21 US disclosed
US-9598386-B2 Immunomodulatory compounds UNIVERSITY OF STRATHCLYDE (GB) 2017-03-21 US disclosed
US-9598386-B2 Immunomodulatory compounds UNIVERSITY OF STRATHCLYDE (GB) 2017-03-21 US disclosed
US-20150218116-A1 Immunomodulatory Compounds UNIVERSITY OF STRATHCLYDE (GB) 2015-08-06 US disclosed
US-20150218116-A1 Immunomodulatory Compounds UNIVERSITY OF STRATHCLYDE (GB) 2015-08-06 US disclosed
US-20150218116-A1 Immunomodulatory Compounds UNIVERSITY OF STRATHCLYDE (GB) 2015-08-06 US disclosed
EP-2882727-A1 IMMUNOMODULATORY COMPOUNDS University of Strathclyde (GB) 2015-06-17 EP disclosed
WO-2014023934-A1 IMMUNOMODULATORY COMPOUNDS UNIVERSITY OF STRATHCLYDE (GB) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218116-A1 Immunomodulatory Compounds TSLP, IL2, ICOS KMT2A 3352/4885MMP1 1728/4885MMP2 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.